007575.KO Ilyang Pharmaceutical Co.,Ltd
- Market cap
- KRW 320B
- P/E
- -
- P/B
- -
- ROE
- 11.4%
- Dividend yield
- 0.90%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 007575.KO undervalued?
Graham numberThe Graham number of Ilyang Pharmaceutical Co.,Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ilyang Pharmaceutical Co.,Ltd fundamental analysis
No fundamental analysis for Ilyang Pharmaceutical Co.,Ltd yet.
Ilyang Pharmaceutical Co.,Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ilyang Pharmaceutical Co.,Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and…
Full company profileIlyang Pharmaceutical Co.,Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ilyang Pharmaceutical Co.,Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 262B | 270B | 300B | 325B | 343B | 371B | 384B | 267B | 269B | 272B | 260B |
| Gross Profit | 123B | 136B | 154B | 179B | 182B | 204B | 216B | 116B | 111B | 116B | 97.8B |
| Operating Income | 23.2B | 24.4B | 16.7B | 32.5B | 34.1B | 41.0B | 40.4B | 16.4B | 9.62B | 4.96B | -28.3B |
| EBITDA | - | 34.9B | 24.6B | 42.0B | 44.1B | 53.6B | 56.9B | 13.4B | 23.7B | 24.6B | 37.1B |
| Net Income | 5.91B | 6.26B | -4.89B | 9.98B | 10.9B | 14.4B | 19.2B | -2.41B | 9.03B | 6.90B | 29.0B |
| EPS | - | 345 | -269 | 548 | 598 | 790 | 1,064 | -134 | 501 | 385 | 1,618 |
| Balance Sheet | |||||||||||
| Total Assets | 431B | 436B | 432B | 437B | 439B | 494B | 498B | 357B | 431B | 457B | 452B |
| Total Liabilities | 214B | 225B | 222B | 215B | 194B | 223B | 206B | 160B | 191B | 216B | 195B |
| Shareholders' Equity | 200B | 192B | 187B | 197B | 207B | 224B | 235B | 196B | 236B | 238B | 253B |
| Cash & Short-term Investments | 13.3B | 23.6B | 22.2B | 35.9B | 41.3B | 47.7B | 59.6B | 79.7M | 4.30B | 23.7B | 12.9B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 27.0B | 30.0B | 22.1B | 36.2B | 57.5B | 67.0B | 29.9B | 14.6B | 5.61B | 12.0B | 39.5B |
| Capital Expenditure | 10.3B | 3.78B | 1.55B | 2.17B | 10.2B | 12.9B | 4.08B | 6.83B | 40.6B | 10.4B | 10.1B |
| Free Cash Flow | - | 20.9B | 12.4B | 27.8B | 32.9B | 45.7B | 9.40B | 7.79B | -35.0B | 1.60B | 29.4B |
| Ratios | |||||||||||
| ROE | 3.0% | 3.3% | -2.6% | 5.1% | 5.3% | 6.4% | 8.2% | -1.2% | 3.8% | 2.9% | 11.4% |
| ROA | 1.4% | 1.4% | -1.1% | 2.3% | 2.5% | 2.9% | 3.9% | -0.7% | 2.1% | 1.5% | 6.4% |
| Net Profit Margin | 2.3% | 2.3% | -1.6% | 3.1% | 3.2% | 3.9% | 5.0% | -0.9% | 3.4% | 2.5% | 11.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ilyang Pharmaceutical Co.,Ltd dividends
- Dividend yield
- 0.90%
- Forward dividend
- 180.00 KRW
- Payout ratio
- 41.7%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 2.88B | 161 | 41.7% |
| 2024 | KRW 2.97B | 165 | 32.9% |
| 2023 | KRW 2.99B | 166 | - |
| 2022 | KRW 3.94B | 218 | 20.5% |
| 2021 | KRW 8.77B | 482 | 61.0% |
| 2020 | KRW 4.90B | 269 | 45.1% |
| 2019 | KRW 5.82B | 319 | 58.2% |
| 2018 | KRW 1.98B | 109 | - |
| 2017 | KRW 5.26B | 290 | 84.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 28, 2006.
Who owns Ilyang Pharmaceutical Co.,Ltd
Ownership data of Ilyang Pharmaceutical Co.,Ltd is not available yet.
Ilyang Pharmaceutical Co.,Ltd company profile
- Company name
- Ilyang Pharmaceutical Co.,Ltd
- Ticker
- 007575.KO
- ISIN
- KR7007571003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 660
- Fiscal year end
- December
- Address
- 110, Hagal-ro, Yongin-si, South Korea, 17096
- Phone
- 82 3 1281 7851
- Website
- home.ilyang.co.kr
About Ilyang Pharmaceutical Co.,Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and beverages. In addition, the company offers pharmaceutical raw materials products, such as aluminum hydroxide gel, dried aluminum hydroxide gel, magnesium hydroxide, magnesium hydroxide gel, aluminum hydroxide-magnesium carbonate co-dried gel, magnesium trisilicate, hydrotalcite, almagate, aluminum phosphate, aluminum phosphate gel, aluminum magnesium metasilicate, aluminum magnesium silicate, aluminum magnesium silicopolydrate, magaldrate, magaldrate wet gel, dihydroxy aluminum sodium carbonate, magnesium carbonate, aluminum magnesium hydroxide, synthetic aluminum silicate, and other products. Ilyang Pharmaceutical Co.,Ltd also exports its products. The company was formerly known as Il-Yang Pharm. Ind. Co. and changed its name to Ilyang Pharmaceutical Co., Ltd. in May 1991. Ilyang Pharmaceutical Co.,Ltd was founded in 1946 and is headquartered in Yongin-si, South Korea.
Ilyang Pharmaceutical Co.,Ltd management
3- Mr. Dong-Yeon KimCEO, President & Director · born 1950
- Mr. Yoo-Suk JungSenior MD & Director · born 1976
- Mr. Kyu-Young ChoiMD & Director · born 1958